AbbVie management check

ABBV · Health Care · Biotechnology · CEO Mr. Michael

Filings as of

68
Management score, ranked 208th of 487 · 24th of 60 in Health Care4 good · 3 to watch · 0 flaggedStrongest: clean books · Weakest: pay for performance · Best and worst run in Health Care →

The seven checks

  • Good

    Have owners done well?

    Beat its chosen peersOwners$259Peers$187

    What $100 became since fiscal 2021

    9977th
    Detail

    $100 invested at the start of fiscal 2021 grew to $259, against $187 for the peer group the company picked itself.

  • Watch

    Does pay follow performance?

    Pay only loosely tracked returns20212025

    Pay actually paid $100 value, each on its own scale

    4811th
    Detail

    Over 5 years, the CEO's pay actually paid (equity valued at the share price) had a correlation of -0.03 with shareholder return. 1 means pay moved in step; below 0, the opposite way.

  • Good

    What does the CEO cost owners?

    0.8% of net income

    $32.5m pay · $4.2bn net income, FY2025

    0.1%1%3%10%
    5960th
    Detail

    $32.5m of reported pay in fiscal 2025, against $4.2bn of net income.

  • Watch

    Do they own the stock?

    Insiders are selling

    6 mo: ▲ $0 bought · ▼ $20.1m sold

    ——
    Detail

    2 insiders sold $20.1m in the last six months and none bought.

  • Good

    Are owners being diluted?

    Share count shrinking2021 · 1.8bn2025 · 1.8bn

    Diluted shares +0.0% a year; flagged above +2%

    0%10%20%

    Stock pay 1.6% of revenue

    5035th
    Detail

    Diluted shares changed +0.0% a year over the last three fiscal years. Stock-based pay was 1.6% of revenue in the latest year.

  • Watch

    Is leadership stable?

    2 CEOs in the pay table

    7 filings under 8-K 5.02 in 3 years

    0101420+

    CEOs: Mr. Michael, Mr. Gonzalez

    5025th
    Detail

    CEOs in the pay table: Mr. Michael, Mr. Gonzalez. 7 filings under 8-K item 5.02 (officers or directors leaving or joining, or new pay arrangements) in the last 3 years.

  • Good

    Are the books clean?

    No red flags on file

    Since 2021

    • 0Restated
    • 0Auditor changes
    • 0Late filings
    • 010-K amended
    100100th
    Detail

    No restatements, auditor changes or late filings since 2021.

  • Reading the scores

    Each check scored 0–100 from its own figure. The tick is the Health Care median; the ordinal is the share of ranked S&P 500 companies it matches or beats.

    Hover a chart for its figures. Detail has the full reading.

Pay versus performance

From the proxy statement filed March 23, 2026.

CEO pay as reportedActually paid ⓘWhat $100 becamePeer group the company chose
$0$33.8m$67.6m$10020212022202320242025$259$187

Pay tied most to Adjusted diluted EPS

Other key measuresAdjusted Diluted Earnings Per ShareRelative Return on Invested CapitalAdjusted Return on AssetsNon-GAAP Income Before TaxesNon-GAAP Operating MarginPlatform RevenueTotal Shareholder Return

Show the figures
Fiscal yearCEOCEO payActually paidOther executives (avg)$100 becamePeersNet income
2025Mr. Michael, Mr. Gonzalez$32.5m$57.4m$12.1m$259$187$4.2bn
2024—$28.5m$67.6m$11.3m$195$151$4.3bn
2023—$25.7m$34.7m$12.3m$164$143$4.9bn
2022—$26.3m$67.4m$9.1m$164$133$11.8bn
2021—$23.9m$66.4m$11.0m$132$123$11.5bn

Insiders and the CEO's stakeSelling

2 insiders sold $20.1m in the last six months and none bought.

Open-market trades by officers and directors since May 21, 2026.

  • SoldJeffrey Ryan StewartEVP, CHIEF COMMERCIAL OFFICER$11.9mNov 9, 2026
  • SoldNicholas DonoghoeEVP, CHIEF BUS/STRAT OFFICER$8.2mAug 14, 2026

Leadership and governance on file

20222023202420252026Leadership 17Votes 5
All 17 filings

Latest shareholder vote results: May 12, 2026, including the say-on-pay vote.

Where the money went

2021–2025: $59.6bn returned to owners in buybacks and dividends, 162% of net income, and $4.0bn of pay in stock.

Net incomeBuybacksDividendsStock-based payDiluted shares
$0$6.4bn$12.7bn20212022202320242025Shares1.78bn1.78bn1.77bn1.77bn1.77bn
Show the figures
Fiscal year20212022202320242025
Revenue$56.2bn$58.1bn$54.3bn$56.3bn$61.2bn
Net income$11.5bn$11.8bn$4.9bn$4.3bn$4.2bn
Stock-based pay$692.0m$671.0m$747.0m$911.0m$955.0m
Buybacks$934.0m$1.5bn$2.0bn$1.7bn$980.0m
Dividends$9.3bn$10.0bn$10.5bn$11.0bn$11.7bn
Diluted shares1777m1778m1773m1773m1773m

Educational only, not investment advice. Figures are as filed with the SEC: pay from the proxy's pay-versus-performance table, capital allocation from 10-K XBRL data, insider trades from Form 4s over the last six months, events from the last 5 years of filings. The peer group is the one the company chose. See the method.